172 related articles for article (PubMed ID: 17903229)
1. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective.
Woodward ER; Sleightholme HV; Considine AM; Williamson S; McHugo JM; Cruger DG
BJOG; 2007 Dec; 114(12):1500-9. PubMed ID: 17903229
[TBL] [Abstract][Full Text] [Related]
2. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
3. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
van der Velde NM; Mourits MJ; Arts HJ; de Vries J; Leegte BK; Dijkhuis G; Oosterwijk JC; de Bock GH
Int J Cancer; 2009 Feb; 124(4):919-23. PubMed ID: 19035463
[TBL] [Abstract][Full Text] [Related]
4. Early detection of breast and ovarian cancer in families with BRCA mutations.
Vasen HF; Tesfay E; Boonstra H; Mourits MJ; Rutgers E; Verheyen R; Oosterwijk J; Beex L
Eur J Cancer; 2005 Mar; 41(4):549-54. PubMed ID: 15737559
[TBL] [Abstract][Full Text] [Related]
5. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
Evans DG; Gaarenstroom KN; Stirling D; Shenton A; Maehle L; Dørum A; Steel M; Lalloo F; Apold J; Porteous ME; Vasen HF; van Asperen CJ; Moller P
J Med Genet; 2009 Sep; 46(9):593-7. PubMed ID: 18413372
[TBL] [Abstract][Full Text] [Related]
6. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.
Partridge EE; Greenlee RT; Riley TL; Commins J; Ragard L; Xu JL; Buys SS; Prorok PC; Fouad MN
Obstet Gynecol; 2013 Jan; 121(1):25-31. PubMed ID: 23262924
[TBL] [Abstract][Full Text] [Related]
7. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
8. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
Lu KH; Skates S; Hernandez MA; Bedi D; Bevers T; Leeds L; Moore R; Granai C; Harris S; Newland W; Adeyinka O; Geffen J; Deavers MT; Sun CC; Horick N; Fritsche H; Bast RC
Cancer; 2013 Oct; 119(19):3454-61. PubMed ID: 23983047
[TBL] [Abstract][Full Text] [Related]
9. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Meeuwissen PA; Seynaeve C; Brekelmans CT; Meijers-Heijboer HJ; Klijn JG; Burger CW
Gynecol Oncol; 2005 May; 97(2):476-82. PubMed ID: 15863147
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
[TBL] [Abstract][Full Text] [Related]
11. [Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience].
Taïeb S; Rocourt N; Narducci F; Leblanc E; Adenis C; Fournier C; Doutrelant P; Peyrat JP; Vennin P
Bull Cancer; 2011 Feb; 98(2):113-9. PubMed ID: 21339094
[TBL] [Abstract][Full Text] [Related]
12. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome.
Gerritzen LH; Hoogerbrugge N; Oei AL; Nagengast FM; van Ham MA; Massuger LF; de Hullu JA
Fam Cancer; 2009; 8(4):391-7. PubMed ID: 19504173
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.
Gaarenstroom KN; van der Hiel B; Tollenaar RA; Vink GR; Jansen FW; van Asperen CJ; Kenter GG
Int J Gynecol Cancer; 2006; 16 Suppl 1():54-9. PubMed ID: 16515568
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
Cortesi L; De Matteis E; Toss A; Marchi I; Medici V; Contu G; Xholli A; Grandi G; Cagnacci A; Federico M
Oncology; 2017; 93(6):377-386. PubMed ID: 28848147
[TBL] [Abstract][Full Text] [Related]
15. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Nyante SJ; Black A; Kreimer AR; Duggan MA; Carreon JD; Kessel B; Buys SS; Ragard LR; Johnson KA; Dunn BK; Lamerato L; Commins JM; Berg CD; Sherman ME
Gynecol Oncol; 2011 Mar; 120(3):474-9. PubMed ID: 21144559
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of women at high risk for hereditary ovarian cancer is inefficient.
Oei AL; Massuger LF; Bulten J; Ligtenberg MJ; Hoogerbrugge N; de Hullu JA
Br J Cancer; 2006 Mar; 94(6):814-9. PubMed ID: 16495917
[TBL] [Abstract][Full Text] [Related]
17. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
[TBL] [Abstract][Full Text] [Related]
18. CA125 Levels in BRCA mutation carriers - a retrospective single center cohort study.
Gebhart P; Singer CF; Gschwantler-Kaulich D
BMC Cancer; 2023 Jul; 23(1):610. PubMed ID: 37393265
[TBL] [Abstract][Full Text] [Related]
19. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
[TBL] [Abstract][Full Text] [Related]
20. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
